The Further cardiovascular OUtcomes Research with proprotein convertase subtilisin–kexin type 9 (PCSK9) Inhibition in subjects with Elevated Risk (FOURIER) trial demonstrated the risk of secondary CVD events among high-risk patients and showed that adding evolocumab to statin therapy reduced the risk of recurrent cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) [13]. This evidence concerns the gene PCSK9 and atherosclerosis.